160 related articles for article (PubMed ID: 38411862)
1. An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness.
Peng H; Feng K; Jia W; Li Y; Lv Q; Zhang Y
Apoptosis; 2024 Jun; 29(5-6):898-919. PubMed ID: 38411862
[TBL] [Abstract][Full Text] [Related]
2. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
[TBL] [Abstract][Full Text] [Related]
3. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.
Sun L; Wang Y; Wang L; Yao B; Chen T; Li Q; Liu Z; Liu R; Niu Y; Song T; Liu Q; Tu K
J Exp Clin Cancer Res; 2019 Apr; 38(1):170. PubMed ID: 30999932
[TBL] [Abstract][Full Text] [Related]
4. microRNA-448 inhibits stemness maintenance and self-renewal of hepatocellular carcinoma stem cells through the MAGEA6-mediated AMPK signaling pathway.
Guo JC; Yang YJ; Zhang JQ; Guo M; Xiang L; Yu SF; Ping H; Zhuo L
J Cell Physiol; 2019 Dec; 234(12):23461-23474. PubMed ID: 31232474
[TBL] [Abstract][Full Text] [Related]
5. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
6. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
7. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
[TBL] [Abstract][Full Text] [Related]
8. Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.
Liu B; Fang X; Kwong DL; Zhang Y; Verhoeft K; Gong L; Zhang B; Chen J; Yu Q; Luo J; Tang Y; Huang T; Ling F; Fu L; Yan Q; Guan XY
J Exp Clin Cancer Res; 2022 May; 41(1):182. PubMed ID: 35610614
[TBL] [Abstract][Full Text] [Related]
9. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
10. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
11. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
12. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Su C; Chen J
Cancer Lett; 2013 Sep; 337(2):226-36. PubMed ID: 23684551
[TBL] [Abstract][Full Text] [Related]
14. TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma.
Zhou S; Du R; Wang Z; Shen W; Gao R; Jiang S; Fang Y; Shi Y; Chang A; Liu L; Liu C; Li N; Xiang R
Cancer Med; 2019 May; 8(5):2325-2337. PubMed ID: 30957973
[TBL] [Abstract][Full Text] [Related]
15. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
16. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts promote the stemness of CD24
Li Y; Wang R; Xiong S; Wang X; Zhao Z; Bai S; Wang Y; Zhao Y; Cheng B
J Mol Med (Berl); 2019 Feb; 97(2):243-255. PubMed ID: 30564864
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
20. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]